Stock Traders Buy High Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 28,871 call options on the company. This represents an increase of approximately 249% compared to the average volume of 8,272 call options.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Guggenheim boosted their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. SVB Leerink started coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 price target for the company. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday. Finally, Citigroup boosted their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.07.

Hims & Hers Health Price Performance

NYSE HIMS opened at $12.36 on Wednesday. The company’s fifty day moving average is $14.04 and its two-hundred day moving average is $10.35. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of -112.27 and a beta of 0.97. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The company’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.05) EPS. As a group, sell-side analysts expect that Hims & Hers Health will post 0.11 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total value of $40,922.40. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at $1,548,080.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Oluyemi Okupe sold 8,509 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $85,345.27. Following the completion of the sale, the chief financial officer now directly owns 161,699 shares in the company, valued at $1,621,840.97. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 4,080 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $10.03, for a total transaction of $40,922.40. Following the transaction, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The disclosure for this sale can be found here. Insiders have sold 736,191 shares of company stock worth $9,733,700 over the last 90 days. 31.63% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Graham Capital Management L.P. raised its position in Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after purchasing an additional 96,277 shares in the last quarter. Swiss National Bank lifted its position in shares of Hims & Hers Health by 9.2% during the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after buying an additional 26,100 shares during the period. Vanguard Group Inc. boosted its stake in Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after buying an additional 428,671 shares in the last quarter. Bank of New York Mellon Corp grew its position in Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after acquiring an additional 58,288 shares during the period. Finally, Must Asset Management Inc. acquired a new position in Hims & Hers Health during the third quarter worth $1,596,000. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.